Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New feature: Introducing the Finviz Matrix

Nkarta, Inc.

Contributing Author

Recent Articles by Nkarta, Inc.

Sep-10	Nkarta to Participate in September Investor Conferences NKTX GlobeNewswire
Sep-08	Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 NKTX +10.62% GlobeNewswire
Aug-10	Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights NKTX NKTX -5.28% GlobeNewswire
Jun-26	Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference NKTX GlobeNewswire
May-12	Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights NKTX NKTX -6.71% GlobeNewswire
Apr-15	Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers NKTX +5.68% NKTX +15.70% GlobeNewswire
Apr-09	Nkarta to Participate in Needham Virtual Healthcare Conference NKTX GlobeNewswire
Mar-25	Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights NKTX GlobeNewswire
Feb-27	Nkarta to Participate in March Investor Conferences NKTX GlobeNewswire
Dec-02	Nkarta to Participate in Evercore Healthcare Conference NKTX GlobeNewswire
Nov-10	Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights NKTX GlobeNewswire
Oct-30	Nkarta to Participate in November Investor Conferences NKTX GlobeNewswire
Oct-22	Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting NKTX -7.95% GlobeNewswire
Sep-02	Nkarta to Participate in a September Investor Conference NKTX GlobeNewswire
Aug-12	Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights NKTX NKTX +12.76% GlobeNewswire
Jul-23	Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series NKTX +7.21% GlobeNewswire
Jun-06	Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus NKTX GlobeNewswire
May-14	Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights NKTX NKTX -8.02% GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)